Breaking Finance News

Zacks Investment Research downgraded Eisai Co., Ltd (ADR) (NASDAQ:ESALY) to Sell in a report released today.

Zacks Investment Research has downgraded Eisai Co., Ltd (ADR) (NASDAQ:ESALY) to Sell in a report released on 10/04/2016.

Yesterday Eisai Co., Ltd (ADR) (NASDAQ:ESALY) traded 0.68% higher at $62.82. The company’s 50-day moving average is $61.45 and its 200-day moving average is $60.39. The last stock close price is up 4.02% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,531 shares of the stock were exchanged, down from an average trading volume of 3,202

See Chart Below

Eisai Co., Ltd (ADR) (NASDAQ:ESALY)

Eisai Co., Ltd (ADR) has a 52 week low of $53.55 and a 52 week high of $67.60 with a P/E ratio of 26.13 The company’s market cap is currently $0.

About Eisai Co., Ltd (ADR) (NASDAQ:ESALY)

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan. The Company offers products, which include Halaven, Aricept, Aloxi, Fycompa, Lenvima, Methycobal, BELVIQ, Pariet, LYRICA, HUMIRA, Lunesta, E5501/AKR-501, BAN2401, Chocola BB Products, E2609 and E2006. The Company's consumer healthcare brand containing Vitamin B is Chocola BB Products. The Company offers a range of products, including Chocola BB Plus, a Vitamin B2 preparation for rough skin and stomatitis, and nutritional supplements and energy drinks, which are available for healthcare needs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *